Entering text into the input field will update the search result below

Atossa up 13% premarket on planned COVID-19 study

  • Atossa Therapeutics (NASDAQ:ATOS) has contracted with NYC Health + Hospitals/Metropolitan in New York City to conduct the NY HOPE Study of Atossa’s combination drug therapy called AT-H201. The study will evaluate AT-H201 in COVID-19 patients on ventilators with the goal of reducing the amount of time on ventilators.
  • The primary objectives are to determine the number of ventilator-free days after patients are removed from ventilators following the initial airway intervention; oxygenation levels; and survival rates.
  • Secondary efficacy endpoints include a variety of lung function parameters and time in ICU.
  • Atossa has filed comprehensive provisional patent applications related to AT-H201.
  • Shares are up 13% premarket.

Recommended For You

About ATOS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ATOS--
Atossa Therapeutics, Inc.